Pharmacologic inhibition of dipeptidyl peptidase 1 (cathepsin C) does not block in vitro granzyme-mediated target cell killing by CD8 T or NK cells.

Autor: Sutton VR; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Watt SV; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Akhlaghi H; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Cipolla DC; Insmed Incorporated, Bridgewater, NJ, United States., Chen KJ; Insmed Incorporated, Bridgewater, NJ, United States., LaSala D; Insmed Incorporated, Bridgewater, NJ, United States., McDonald PP; Insmed Incorporated, Bridgewater, NJ, United States., Beavis PA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Munoz I; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Hodel AW; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Noori T; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Voskoboinik I; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Trapani JA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.

Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2024 Jul 03; Vol. 15, pp. 1396710. Date of Electronic Publication: 2024 Jul 03 (Print Publication: 2024).

The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species.

Autor: Basso J; Insmed Incorporated, Bridgewater, NJ, United States., Chen KJ; Insmed Incorporated, Bridgewater, NJ, United States., Zhou Y; Insmed Incorporated, Bridgewater, NJ, United States., Mark L; Insmed Incorporated, Bridgewater, NJ, United States., LaSala D; Insmed Incorporated, Bridgewater, NJ, United States., Dorfman A; Insmed Incorporated, Bridgewater, NJ, United States., Atalla M; Insmed Incorporated, Bridgewater, NJ, United States., Chun D; Insmed Incorporated, Bridgewater, NJ, United States., Viramontes V; Insmed Incorporated, Bridgewater, NJ, United States., Chang C; Insmed Incorporated, Bridgewater, NJ, United States., Leifer F; Insmed Incorporated, Bridgewater, NJ, United States., McDonald PP; Insmed Incorporated, Bridgewater, NJ, United States., Cipolla DC; Insmed Incorporated, Bridgewater, NJ, United States.

Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2023 Jul 19; Vol. 14, pp. 1208780. Date of Electronic Publication: 2023 Jul 19 (Print Publication: 2023).

Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery.

Autor: Plaunt AJ; Insmed Incorporated, Bridgewater, NJ 08807, USA., Nguyen TL; Insmed Incorporated, Bridgewater, NJ 08807, USA., Corboz MR; Insmed Incorporated, Bridgewater, NJ 08807, USA., Malinin VS; Insmed Incorporated, Bridgewater, NJ 08807, USA., Cipolla DC; Insmed Incorporated, Bridgewater, NJ 08807, USA.

Publikováno v: Pharmaceutics [Pharmaceutics] 2022 Jan 27; Vol. 14 (2). Date of Electronic Publication: 2022 Jan 27.

Inhaled Liposomal Ciprofloxacin Nanoparticles Control the Release of Antibiotic at the Bronchial Epithelia

Autor: Ong, HX, Cipolla, DC, Gonda, I, Traini, D, Bebawy, M, Agus, H, Young, PM

The cycle of respiratory tract infection (RTI) and inflammation in patients with chronic obstructive lung diseases, such as cystic fibrosis (CF), periodically develops into exacerbations, where chronic colonization of the airway by bacteria causes se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______363::8f0cb064f1b6b323912566b1b05617ec
https://hdl.handle.net/10453/31081

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.